KD INVESTOR ALERT: Kyndryl Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead the Class Action Lawsuit [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 13, 2026 /PRNewswire/ -- The law firm of [Robbins Geller Rudman & Dowd LLP] announces that purchasers or acquirers of Kyndryl Holdings, Inc. (NYSE: KD) publicly traded securities between August 7, 2024 and February 9, 2026, inclusive (the "Class Period"), have until April 13, 2026 to seek appointment as lead plaintiff of the Ky ...

Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. on behalf of investors who acquired its securities during the specified Class Period, alleging misleading statements regarding the company's financial health and operations [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who purchased Beyond Meat securities from February 27, 2025, to November 11, 2025 [1][2]. - Investors have until March 24, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Company Performance and Statements - Throughout the Class Period, Beyond Meat claimed it was focused on achieving EBITDA-positive operations by the end of 2026, emphasizing cost reductions and gross margin expansion while downplaying revenue growth [3]. - The complaint alleges that Beyond Meat's statements were materially false and misleading, as the company failed to disclose impairments of long-lived assets and the likelihood of a significant non-cash impairment charge [4]. Group 3: Stock Impact - On October 24, 2025, Beyond Meat announced it expected to record a material impairment charge, leading to a stock price drop of over 23% in one trading day [4]. - Subsequent disclosures in November 2025 regarding delayed SEC filings and $77.4 million in impairment charges resulted in further stock declines of approximately 16%, 9%, and 9%, causing substantial losses for investors [4].

Core Viewpoint - Kaskela Law LLC has initiated an investigation on behalf of Houlihan Lokey, Inc. shareholders to assess potential violations of securities laws or breaches of fiduciary duties by the company and its officers in relation to recent corporate actions [1]. Group 1 - The investigation is focused on determining whether Houlihan Lokey and its leadership acted inappropriately concerning the interests of investors [1]. - Shareholders of Houlihan Lokey are encouraged to reach out to Kaskela Law LLC for more information regarding their legal rights and options [2]. - Kaskela Law LLC specializes in representing investors in cases of securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis [2].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Company Overview - BellRing Brands, Inc. develops, markets, and sells "convenient nutrition" products, primarily known for its ready-to-drink protein shakes under the Premier Protein brand [3]. Allegations of Securities Fraud - The lawsuit claims that BellRing misrepresented its sales growth as being driven by increased consumer demand, attributing it to "organic growth," "distribution gains," and "strong macro tailwinds around protein," while downplaying competitive pressures [3]. - It is alleged that the actual sales growth was due to key customers stockpiling inventory rather than genuine consumer demand, and that competitive pressures were materially weakening demand [3]. Stock Price Decline - On May 6, 2025, BellRing's CFO announced that several key retailers had reduced their inventory levels, leading to a projected mid-single-digit headwind for Q3 growth, resulting in a stock price drop of $14.88 per share, or 19%, from $78.43 to $63.55 [4]. - Following the Q3 2025 financial results reported on August 4, 2025, which included a narrowed fiscal year outlook due to increased competition, the stock price fell by $17.46 per share, nearly 33%, from $53.64 to $36.18 on August 5, 2025 [5][6].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of New York, captioned Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. - Investors have until April 3, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Plug Power specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets, and develops infrastructure such as hydrogen production plants [4]. - The company announced a "closed a $1.66 billion loan guarantee" from the U.S. Department of Energy to finance the construction of hydrogen production facilities [4]. Group 3: Stock Performance and Events - On October 7, 2025, Plug Power's stock dropped by $0.26 per share (6.3%) following the abrupt departure of its CEO and President [5]. - On November 10, 2025, the company announced the suspension of activities under the DOE loan program, leading to a stock drop of $0.09 per share (3.4%) [6]. - On November 13, 2025, it was reported that Plug Power confirmed the suspension of plans to construct hydrogen facilities, resulting in a stock drop of $0.48 per share (17.6%) [7].

Core Viewpoint - A class action lawsuit has been initiated against uniQure N.V. for alleged securities fraud, with a focus on misrepresentations regarding the company's drug candidate and regulatory approvals [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1] - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [1] Group 2: Legal Representation - Rosen Law Firm, known for its success in securities class actions, is leading the lawsuit and encourages investors to select qualified counsel [1] - The firm has a strong track record, having achieved significant settlements for investors, including over $438 million in 2019 [1] - Investors can join the class action by contacting Rosen Law Firm through their website or phone [1] Group 3: Implications for Investors - The lawsuit alleges that when the true details about uniQure's business and operations were revealed, investors suffered damages [1] - A lead plaintiff is needed to represent the class, and interested parties must move the Court by April 13, 2026 [1] - Until the class is certified, investors are not represented by counsel unless they retain one [1]

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. for securities fraud, alleging that the company made false statements and failed to disclose material issues regarding its financial statements and internal controls during the class period from August 7, 2024, to February 9, 2026 [1][1][1] Summary by Relevant Sections Lawsuit Details - The lawsuit claims that Kyndryl's financial statements were materially misstated and that the company lacked adequate internal controls, which led to an inability to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025 [1][1][1] - It is alleged that the misleading statements about Kyndryl's business operations and prospects caused investors to suffer damages when the true details became public [1][1][1] Class Action Participation - Investors who purchased Kyndryl securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][1][1] - To join the class action, investors can visit the provided link or contact the law firm directly for more information [1][1][1] Law Firm Background - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [1][1][1] - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [1][1][1]

Core Viewpoint - Pomerantz Law Firm is investigating potential securities fraud and unlawful business practices by Ashford Hospitality Trust, Inc. and its officers or directors [1] Group 1: Company Actions - On January 13, 2026, Ashford announced the extension of its Highland mortgage loan secured by 18 hotels [1] - To maintain liquidity while evaluating strategic alternatives, Ashford suspended preferred dividends for various series of preferred stock, including those declared for record holders as of December 31, 2025, payable on January 15, 2026 [1] Group 2: Market Reaction - Following the announcement, Ashford's stock price decreased by $0.35 per share, representing an 8.1% decline, closing at $3.97 per share on January 13, 2026 [1]

Core Viewpoint - A securities class action lawsuit has been filed against F5, Inc. for alleged violations of the Securities Exchange Act of 1934 during the Class Period from October 28, 2024, to October 27, 2025, with a lead plaintiff deadline set for February 17, 2026 [1] Group 1: Lawsuit Details - The lawsuit, titled Smith v. F5, Inc., claims that F5 and its executives misrepresented the company's revenue outlook and growth potential while downplaying risks associated with seasonality and macroeconomic factors [1] - Allegations include that F5 was experiencing a significant security incident that jeopardized client security and the company's future prospects [1] - On October 15, 2025, F5 disclosed a security breach involving a nation-state threat actor, leading to a nearly 14% drop in stock price over two trading days [1] Group 2: Financial Impact - Following the security breach, F5 reported fourth quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026, attributing this to the breach and announcing expected reductions in sales and renewals [1] - The stock price fell nearly 11% over two trading days after the announcement of the disappointing fiscal results [1] Group 3: Legal Process - Investors who purchased F5 securities during the Class Period can seek appointment as lead plaintiff, with the lead plaintiff representing the interests of all class members [1] - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [1] Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [1]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Picard Medical, Inc. of Class Action Lawsuit and Upcoming Deadlines - PMI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Picard Medical, Inc. ("Picard" or the "Company") (NYSE: PMI). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 798 ...